Earnings call transcript: TransMedics Q1 2026 misses EPS forecast, stock stable

TransMedics reported Q1 2026 EPS of $0.30 versus $0.62 consensus, a 51.6% miss, while revenue of $173.9 million came in slightly below the $174.47 million estimate. Revenue still grew 21% year over year, but gross margin fell 331 bps to 58% and adjusted operating expenses rose 42%, signaling heavier investment and margin pressure. Management reiterated full-year 2026 revenue guidance of $727 million-$757 million and highlighted CHOPS, OCS Kidney, and Europe expansion as key growth drivers.

Analysis

TMDX is transitioning from a clean growth story to a “funding-the-future” story, and that matters more than the headline EPS miss. The market is likely rewarding the fact that management is intentionally compressing near-term earnings to defend multiple expansion on a much larger TAM: if CHOPS and the kidney platform work, they convert TMDX from a cardiothoracic logistics/tooling company into a broader organ-preservation platform with multiple monetization vectors. The second-order effect is that the company is using product breadth to make its clinical trials less dependent on external comparators, which can reduce competitive interference and tighten control over commercial adoption.

The real battleground is not the quarter; it is whether the investment cycle creates enough operating leverage before the next leg of regulatory and clinical spend lands. Gross margin being capped around the high-50s while opex grows 40%+ means the stock is effectively pricing in a sustained re-acceleration in case volume and logistics utilization over the next 2-4 quarters. If donor volatility tied to modernization pressure persists into Q2/Q3, investors will start to question whether this is a temporary timing issue or a structural ceiling on utilization growth, especially in a business whose service mix amplifies fixed-cost leverage.

The contrarian angle: the CHOPS launch may be more strategically important for market share defense than for immediate incremental revenue. It gives TMDX a way to own the short-duration, cold-storage segment that it previously ceded, which can reduce the risk that competitors use that niche as an entry point to block broader platform adoption. But it also creates execution risk: if the control-arm redesign blurs trial interpretation or pushes commercialization later than expected, the stock could de-rate quickly because current valuation is still underwriting multiple catalysts simultaneously, not just one.

Key Decisions for Investors

• Maintain a tactical long TMDX into the next 4-8 weeks only if the stock holds above the post-earnings level and management lands the IDE supplement timeline; downside is a fast de-rate if Q2 donor volumes remain weak.
• Use call spreads rather than outright equity for TMDX 3-6 months out; the catalyst stack is real, but operating margin compression makes the left tail ugly if trial timing slips.
• Pair trade: long TMDX / short a basket of transplant-exposed medtech or logistics names over 1-2 quarters, betting that TMDX is better positioned to re-segment the market than peers that lack an integrated service layer.
• If you want to fade the optimism, buy downside protection on TMDX ahead of the next donor-volume update; that is the cleanest near-term reversal trigger and should matter more than the reported revenue miss.
• Avoid chasing the aftermarket strength; wait for either confirmation that CHOPS clears the regulatory gate or for a better entry on a broader market risk-off tape, since the stock is now priced as a multi-catalyst story rather than a simple earnings beat/miss name.